Thermo Fisher And Danaher Could Find Their Growth Groove Again
UBS expects Thermo Fisher (TMO) to achieve 5-6% organic growth and 50-70 basis points of margin expansion, leading to double-digit EPS growth. Danaher (DHR) may return to mid-single-digit growth next year, potentially regaining its valuation premium over peers. Both companies could see improved performance due to operating leverage.
How this was made
The 30-second read
Why it matters
The commentary suggests upside potential but lacks concrete new data.
Market read
Analyst outlook may influence sector sentiment but offers no immediate trading trigger.
What to watch
Potential supply‑chain constraints in China could hinder margin recovery.
Background
UBS analyst note discussing growth and margin outlook for Thermo Fisher and Danaher.
Ticker impact
Analyst UBS projects 50-70 bps margin expansion and double‑digit EPS growth for Thermo Fisher.
Modest upside if margin targets are achieved.
Margin expansion is a lever for earnings growth, but guidance is still forward‑looking.
UBS expects Danaher to return to mid‑single‑digit organic growth after bioprocessing slip.
Potential incremental upside if growth re‑accelerates.
Growth outlook is speculative; actual execution will determine impact.
Market effects
Life‑sciences tools sector could see modest re‑rating if margin and growth targets are met.
Limited to U.S. and global biotech investors.
Low; primarily affects sector‑specific funds.
Counterpoint
Margin targets may be overly optimistic given recent demand softness.
Key entities
- companyThermo Fisher Scientific
Life‑sciences equipment and services provider.
- companyDanaher
Diversified industrial and life‑sciences conglomerate.
%252FHealthcare%252520researchers%252520working%252520in%252520medical%252520lab%252520by%252520chokniti%252520via%252520Adobe%252520Stock.jpeg&w=2048&q=75)